Scancell Holdings (LSE:SCLP) EBIT

: £-10.82 Mil (TTM As of Oct. 2023)

View and export this data going back to 2010. Start your Free Trial

Scancell Holdings's earnings before interest and taxes (EBIT) for the six months ended in Oct. 2023 was £-3.10 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Oct. 2023 was £-10.82 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Scancell Holdings's annualized ROC % for the quarter that ended in Oct. 2023 was -141.06%. Scancell Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Oct. 2023 was -153.62%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Scancell Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Oct. 2023 was -11.33%.

Scancell Holdings EBIT Historical Data

The historical data trend for Scancell Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

EBIT

-6.73

-6.77

-15.15

-4.50

-13.09

Scancell Holdings Semi-Annual Data
	Apr14	Oct14	Apr15	Oct15	Apr16	Oct16	Apr17	Oct17	Apr18	Oct18	Apr19	Oct19	Apr20	Oct20	Apr21	Oct21	Apr22	Oct22	Apr23	Oct23
EBIT																4.22	-8.71	-5.37	-7.72	-3.10

Competitive Comparison

For the Biotechnology subindustry, Scancell Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scancell Holdings EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Scancell Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's EV-to-EBIT falls into.

Scancell Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Oct. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-10.82 Mil.

Scancell Holdings (LSE:SCLP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Scancell Holdings's annualized ROC % for the quarter that ended in Oct. 2023 is calculated as:

	ROC % (Q: Oct. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Apr. 2023 )	+	Invested Capital (Q: Oct. 2023 ))	/ count )
=	-16.24 * ( 1 - 28.99% )	/	( (8.842	+	7.509)	/ 2 )
=	-11.532024	/	8.1755
=	-141.06 %

where

	Invested Capital		(Q: Apr. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	30.27	-	1.508	-	( 19.92	-	max(0, 3.276	-	24.606	+	19.92	))
=	8.842

	Invested Capital		(Q: Oct. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	22.252	-	1.664	-	( 13.079	-	max(0, 1.97	-	17.009	+	13.079	))
=	7.509

Note: The Operating Income data used here is two times the semi-annual (Oct. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Scancell Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Oct. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Oct. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Apr. 2023		Q: Oct. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-6.19	/	( ( (2.249 + max(1.716, 0))	+	(1.828 + max(2.266, 0)) )	/	2 )
=	-6.19	/	( ( 3.965	+	4.094 )	/	2 )
=	-6.19	/	4.0295
=	-153.62 %

where Working Capital is:

	Working Capital		(Q: Apr. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.538	+	0	+	4.148)	-	(1.508	+	0	+	1.462)
=	1.716

	Working Capital		(Q: Oct. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.476	+	0	+	3.454)	-	(1.664	+	0	+	0)
=	2.266

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Oct. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Scancell Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Oct. 2023 )
	=	-10.815	/	95.454
	=	-11.33 %

Scancell Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Scancell Holdings (LSE:SCLP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (LSE:SCLP) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

SCLP.GB:UK SCP:Germany

Address

Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD

Website

https://www.scancell.co.uk

Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (LSE:SCLP) Headlines

No Headlines